Anwar Hussain
About Anwar Hussain
Anwar Hussain is a Senior Scientist specializing in stability at Bristol-Myers Squibb, with over 25 years of experience in the pharmaceutical industry.
Company
Anwar Hussain is currently employed at Bristol-Myers Squibb in Princeton, New Jersey. His tenure at the company began in January 2011, and he holds the title of Senior Scientist, specializing in stability. Prior to this role, he also served the company as a Senior Research Scientist from 1998 to 2007.
Title
Anwar Hussain holds the position of Senior Scientist - Stability at Bristol-Myers Squibb. His work primarily focuses on ensuring the quality and shelf-life of pharmaceutical products, and conducting stability studies to support regulatory submissions and product launches.
Education and Expertise
Anwar Hussain possesses a strong educational background comprising a BA in Biochemistry from Rutgers University (1985-1989), an MS in Medicinal Chemistry from the University of North Carolina at Chapel Hill (1992-1996), and an MBA specializing in Product Management and Entrepreneurship from UNC Kenan-Flagler Business School (2007-2009). His expertise bridges both scientific and business domains, combining technical knowledge with strategic management skills.
Background
Anwar Hussain has over 25 years of experience in the pharmaceutical industry. He began his career as a Staff Scientist at Xenobiotic Laboratories (1996-1998) before moving to Bristol-Myers Squibb where he worked as a Senior Research Scientist for nine years (1998-2007). He also served as MBA Summer Intern at Closure Medical/Ethicon/Johnson and Johnson (2008) and was a Senior Chemistry Analyst at Hospira (2010) before returning to Bristol-Myers Squibb in 2011.
Achievements
Anwar Hussain has played a crucial role in conducting stability studies that support regulatory submissions and product launches, thereby ensuring the quality and shelf-life of pharmaceutical products. His extensive experience in both chemistry and business has enabled him to effectively contribute to the pharmaceutical industry for over two and a half decades.